Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the Firm

NEW YORK, Oct. 28, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

logo (PRNewsfoto/Halper Sadeh LLP)

FTS International, Inc. (NYSE: FTSI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ProFrac Holdings, LLC for $26.52 per share in cash. If you are an FTS International shareholder, click here to learn more about your rights and options.

Umpqua Holdings Corporation (NASDAQ: UMPQ) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Columbia Banking System, Inc. Under the terms of the agreement, Umpqua shareholders will receive 0.5958 of a share of Columbia stock for each Umpqua share they own. Upon completion of the transaction, Umpqua shareholders will own approximately 62% of the combined company. If you are an Umpqua shareholder, click here to learn more about your rights and options.

Flexion Therapeutics, Inc. (NASDAQ: FLXN)concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Pacira BioSciences, Inc. for $8.50 per share in cash plus one non-tradeable contingent value right worth up to $8.00 per share in cash. If you are a Flexion shareholder, click here to learn more about your rights and options.

Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Supernus Pharmaceuticals, Inc. for $8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash. If you are an Adamas shareholder, click here to learn more about your rights and options.

Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llp-investigates-ftsi-umpq-flxn-adms-shareholders-are-encouraged-to-contact-the-firm-301411191.html

SOURCE Halper Sadeh LLP